options for the treatment of type 2 diabetes and I would like to live in a system in which
innovation is encouraged, not discouraged even passively. While I obviously support the
objectives, fully support the objectives, of assuring safety of all drugs including for
diabetes, I strongly encourage FDA and its advisors not to put excessive barriers in the
path of development that will threaten innovation and investment. Please consider this as
new drugs come before for you.
and underscore that this lack of good diabetes management is an economic issue. It’s an
economic issue and it’s a moral issue. We need new drugs so that people can get earlier
and more aggressive treatment that they will take so we can work to prevent and/or delay
diabetes complications. Of course even if people achieve better diabetes management we
know that diabetes is a progressive disease at present. So we would also, if we were
making a list of what patients wanted, say that we would like disease-modifying drugs.
This seems unlikely to happen unless we are in a system that encourages innovation.
That’s what the US is all about and I would hate as a patient to see that stifled.
leading cause of nothing, as Dr. Bill Polonsky says of the Behavioural Diabetes Institute.
Although we hear a lot these days about prevention of diabetes, I would urge the
committee to consider the delay and prevention of complications by considering new
alternatives that will help patients, particularly early in the course of the disease. For the
patients and families of the 24 million adults with diabetes in the US and for 57 million
In closing, my two central messages are: we continue to need alternate
Thank you very much for your time. Well-controlled diabetes is the
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
inexpensive therapy alternatives for a patient so they can do more to help themselves
so that we can do more to help ourselves.
In case I wasn’t clear, let me tie this to the most important issue of our day